Cytodyn Inc (CYDY)

[The Lawman]

It is far more likely that directors, or members of the SAB, are communicating with the FDA on the company's behalf as Pourhassan does not have the scientific background that would enable him to be able to intelligently communicate on the FDA level.

Not only does Pourhassan have no skin in the game, he is being paid over $600,000 per year, per the 2015 10-K, plus warrants. For that kind of money, we could have a president with biopharma experience who has successfully navigated the FDA waters, and brought a clinical stage company to the point of being bought out.